ASX ANNOUNCEMENT | 30 October 2026

Imagion Biosystems' Announces NED Resignation and Change of Company Secretary

Imagion Biosystems (ASX: IBX) (**Company** or **Imagion**), a company dedicated to improving healthcare outcomes through early and more accurate detection of cancers, today announces that Ms Melanie Leydin has advised the Company of her intention to resign from her role as a Non-Executive Director and Company Secretary of the Company, effective 30 October 2026, coinciding with her retirement and desire to focus on other external commitments. Ms Leydin joined the Imagion Board in August of 2024.

As part of its ongoing governance and leadership planning, the Board is reviewing its composition and the skills required to support the Company through its next stage of clinical and commercial development. The Board expects this process to include consideration of an additional independent Non-Executive Director, if and when appropriate.

Ms Mariia Skorikova and Mr Tony Di Pietro will be appointed as Joint Company Secretaries, replacing Ms Leydin in her capacity as Company Secretary effective 30 October 2026.

Mariia is an accomplished corporate lawyer and governance professional with over 9 years of experience advising ASX-listed and unlisted entities across diverse industries.

Tony is a Chartered Accountant and Fellow of the Australian Governance Institute with over 20 years of corporate accounting and governance experience, gained both in Australia and the UK. Mr Di Pietro has held a number senior executive roles throughout his career.

For the purposes of Listing Rule 12.6, Mariia and Tony will be the persons responsible for communications between the Company and the ASX in relation to ASX Listing Rule matters.

On behalf of the Board, management and shareholders, Imagion thanks Ms Leydin for her contribution to the Company. During her tenure, Ms. Leydin has provided valuable financial guidance and governance oversight, helping support the Company through a period of restructuring and the advancement of its clinical development programs.

Bob Proulx, Executive Chairman said, "I would like to thank Ms Leydin for her work and support of Imagion and wish her well in her next endeavors."

Authorisation & Additional Information

This announcement was authorised by the Board of Imagion Biosystems Limited.

Join Imagion Biosystems' Investor Hub

Stay up to date on news and announcements or interact with our team through questions and comments via Investor Hub. Register at investor.imagionbiosystems.com.

###

About Imagion Biosystems

Imagion Biosystems (ASX: IBX) is a clinical-stage, medical imaging company dedicated to transforming how cancer is diagnosed and treated. The company produced and is developing clinical applications for MagSense®, a first-of-its-class MRI imaging agent that enables clinicians to detect cancer earlier and with greater precision. Advancing molecular MRI, the company is using non-radioactive, bio-safe magnetic nanoparticles to improve diagnostic certainty for a broad range of applications, including HER2+ breast cancer, prostate cancers, and ovarian cancers. For more information, visit imagionbiosystems.com.

Executive Chairman Contact Details
Bob Proulx
investor@imagionbio.com
AU: +61 3 9692 7222

Media Enquiries & Investor Relations
Erich Boileau, Boileau & Co.
imagionbio@boileau.co
US : +1 (616) 786-4461